Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

1.172 -0.008 (-0.65%)
Streaming Delayed Price Updated: 11:20 AM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 151,205
Open 1.190
Bid (Size) 1.170 (22)
Ask (Size) 1.180 (22)
Prev. Close 1.180
Today's Range 1.170 - 1.200
52wk Range 1.025 - 2.850
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Via Benzinga
Exposures Product Safety

Performance

YTD
-30.63%
-30.63%
1 Month
-10.51%
-10.51%
3 Month
-9.82%
-9.82%
6 Month
-34.51%
-34.51%
1 Year
-7.69%
-7.69%

More News

Read More
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
Via Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
Via Talk Markets
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From atai Life Sciences
Via GlobeNewswire
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
Via Talk Markets
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
Via Benzinga
ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024
Via InvestorPlace
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
From atai Life Sciences
Via GlobeNewswire
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Via Benzinga
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
3 Dirt-Cheap Drug Developers With Blockbuster Potential
Via InvestorPlace
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
Via InvestorPlace
3 Psychedelic Stocks to Ride to the Moon and Beyond
Via InvestorPlace
Exposures Product Safety
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
Via InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
Via InvestorPlace
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Via Talk Markets
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
From atai Life Sciences
Via GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
From atai Life Sciences
Via GlobeNewswire
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.